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DETECTION OF ANTI-IDIOTYPIC ANTIBODIES AFTER OKT3 TREATMENT BY FLOW CYTOMETRY 
We read the interesting article by McIntyre and Higgins 
(1) describing a rapid assay to detect anti-idiotypic anti-
OKT3 antibodies generated after treatment with OKT3 with 
the help of the Jurkat cell line. We have developed an anal-
ogous method and measured the amount of anti-idiotypic 
antibodies in heart and kidney transplant recipients after 
OKT3 therapy, using the human T cell line HPB-ALL (2, 3). 
The HPB-ALL cell line is, like Jurkat, easy to grow in sus-
pension, but it generates a more homogenous population in a 
flow cytometer analysis in terms of forward and side scatter. 
In addition, the HPB-ALL cell line has a higher OKT3 bind-
ing capacity (185 x 103 vs. 73 X 103 CD3 determinants/cell), 
providing a more intense fluorescence signal with FITC-con-
jugated OKT3 (4). We agree with the authors, that this 
method is specific for measuring anti-idiotypic antibodies 
against the therapeutically used antibody. The specificity of 
our test was confirmed with two other anti-CD3 antibodies, 
i.e., BMA 030 and BMA 033. mouse monoclonal antibodies of 
an identical (IgG2n) and a different isotype (lgG3), respec-
tively. 
We eliminated the interference of common anti-mouse an-
tibodies by preincubating patient plasma with normal mouse 
serum before adding FITC-OKT3. We have calculated the 
amount of OKT3 captured by anti-idiotypic antibodies in the 
plasma samples. Therefore. we measured the fluorescence of 
HPB-ALL-bound FITC-OKT3 in the presence of different 
quantities of FITC-OKT3 in the absence of plasma and we 
compared this curve with the one generated in the presence 
of patient plasma. The shorter procedure of McIntyre and 
Higgins results in a titer of anti-idiotypic antibodies without 
an indication of the influence of these anti-idiotypic antibod-
ies on the amount of available OKT3 in the plasma in case of 
retreatment with OKT3. 
In conclusion, we agree that this method is suitable for 
monitoring patients. 
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DONOR-RECIPIENT MICROCHIMERISM AND TOLERANCE INDUCTION 
The fully allogeneic mouse strain combination ofC5/BUlO 
I BI0) donor - C3H1He recipient E~leC class I. II, MHC 
disparate) allows routine spontaneous acceptance of liver 
allografts but not of abdominally placed hearts that are re-
Jected alter 8 days Ill. Bushell et al. (2) described prolonga-
tion of B 10 heart survival determined by palpable graft con-
traction andJor EKG activity. follOWing ~ kinds of donor-
specific I. OS) blood priming 24-28 days before surgery. 
However. to be effective. the pnming had to be done under a 
two-dose cover of depleting antI-COol monoclonal antibody. 
.\ided by the antibody treatment (which had no etfect alone!. 
,;lngle unmodified DS transfUSIOn allowed 70% > IOO-day 
).,'!"att sUrvlval versus 60% if 4 daily transfUSIOns of irradiated 
OS blood were gwen. At face value. the conclusion from this 
complex expenment is that both live donor leukocytes and 
dead donor antigen can be tolerogenic but with very different 
efficacy. This conclusion was the same one as that reached in 
principle by Billingham. Brent. and Medawar (3) four de-
cades ago and venfied frequently since then. 
The question raised by Bushell et al. (2) is whether leuko-
cvte chimerism is required for permanent tolerance. The 
;nswer was ves from the studies of Russell (4). who showed 
that chimeri~m-associated tolerance to stable skin grafts in 
the Billingham-Brent-Medawar mouse model was abolished 
bv eliminatIOn of the chimeric cells (with isoantibodies I. Sim-
il~rlyI LubarotT and Silvers (.;) demonstrated in classical 
expenments with such isoantibodies that the loss of estab-
lished skin allografts In mice usually required many days or 
weeks. retlectmg the gradual decay of tolerance. The exper-
iments of Bushell et al. (2) are less easy to interpret. OS 
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nonreactivity, whether induced by leukocytes or dead anti-
gen (with obviously different degrees of efficacy), can create a 
recipient environment conducive to the acceptance of a sub-
sequently transplanted allograft which brings its own supply 
of chimeric cells. However, quantification of the priming ef-
fect by the endpoints of either cardiac contraction or "lack of 
electrical activity" of the graft is imprecise. The use of chronic 
rejection for an endpoint in such mouse heart transplant 
models as described by Orosz et al. (6) would have been 
definitive. In analogous rat cardiac transplant models done 
in our laboratory, the slow disappearance of chimeric leuko-
cytes correlated closely with chronic rejection of the hetero-
topic allografts which continued to beat (by palpation) for at 
least 2 months after chimerism could no longer be detected 
with immunocytochemical technology (7). Subsequent poly-
merase chain reaction studies revealed scattered foci of donor 
DNA (unpublished observations). 
Thus, the elegant experiments of Bushell et al. (2) are 
entirely congruent with, rather than being contradictory of, 
our hypothesis ascribing a seminal role to microchimerism in 
graft acceptance (8). Viable migratory donor leukocytes (or 
the white cells contained in a nonirradiated DS transfusion) 
are a potentially continuous source of tolerizing antigen. 
However, because these cells have immunologic capability, 
they introduce complex mechanisms of peripheral tolerance 
induction in addition to the presence of antigen as discussed 
elsewhere (8-10). We have shown that the peripheralized 
chimeric leukocytes exhibit qualitatively similar initial pat-
terns of chimerism after liver and heart transplantation (11). 
In our mouse and rat studies, establishment of progenitor 
(and possibly stem) cells (12, 13) as well as the presence of 
mature cells of various lineages (J, 7, 11) correlated with 
permanent acceptance of livers (2, 11). In contrast, the 
smaller dose of migratory leukocytes from heart grafts, less 
favorable lineage composition, or perhaps other factors pre-
cluded achievement of a self-perpetuating chimeric state in 
these rodent recipients (13), The heart recipients in both 
experiments performed by Bushell et al. (2) were given a 
"hooster" toward (but presumably still short of) permitting 
permanent donor leukocyte self-renewal. but to what extent 
is not analyzable without histopathologic data. 
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DONOR-RECIPIENT MICROCHIMERISM AND TOLERANCE INDUCTION (REPL Yl 
The central pomt of our paper published recently in Trans· 
plantatIOn \ 1) is that. when given on 4 consecutive days 
under the cover of antl-CD4 monoclonal antibody therapy, 
nonVIable Irradiated cells were as effectwe as their freshly 
isolated counterparts given on a single occasion. Thus, viable 
cells \ and hence the potential for mlcrochimensmJ were not 
reqUIred to induce the long-term survival of a subsequent 
:Illogralt in this model. 
The success of the anti-CD41DST protocol developed in this 
laboratory depends on interactIOns between donor cells and 
reCIpient T cells during a 3-day perIod of CD4 occupation by 
antibody (laJ. The finding that a SingLe dose of irradiated 
cells given under the cover of antl-CD4 antibody led to acute 
graft rejection is entirely consistent with our Immunocyto-
chemistry studies. which show that while donor cells from a 
normal DST can be detected in recipient spleens for at least 
:3 days after InJectIOn. Irradiated cells are undetectable atter 
about 24 hr. Irradiated cells are thus unable to persIst long 
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enough for the required interactions with antibody-positive 
CD4'" T cells to occur. We speculated that if the persistence 
of nonviable cells within the spleen could be enhanced during 
the period of anti-CD4 antibody occupation, graft prolonga-
tion rather than acute rejection might result. AB shown in our 
Figure 3 (1), this speculation proved to be correct. Adminis-
tration of 3 additional doses of irradiated cells led to graft 
prolongation, which was indistinguishable from that ob-
tained with the basic anti-CD4IDST protocol. These data 
confirm that, in this model, viable cells are not an absolute 
requirement for the induction of unresponsiveness. It is 
worth noting that other studies have also shown that trans-
plantation tolerance can be induced using a variety of non-
viable donor antigen preparations (2, 3). 
Starzl et al. allude to the possibility that migratory cells 
from the graft may play a role in the induction or mainte-
nance of the unresponsive state. While we cannot formally 
rule out this possibility, we think it unlikely for a number of 
reasons. First, recipients pretreated with either anti-CD4 
antibody alone or DST alone 28 days before transplantation 
show only slight graft prolongation (4, 5), which indicates 
that. even in modified hosts, the heart itself is unable to 
provide sufficient migratory cells to make a major contribu-
tion to the development of unresponsiveness. Second, in a 
series of experiments designed to explore the importance of 
the graft itself on the maintenance of tolerance, Hamano et 
a1. (6) transplanted B10 hearts into C3H recipients under the 
cover of perioperative anti-CD4 antibody. Fifty days after 
transplantation, the primary grafts were removed and the 
animals were transplanted with second donor-specific hearts 
60, 130, or 200 days later. While second hearts transplanted 
60 or 130 days after removal of the primary graft were 
accepted (median survival time [MST] > 100 days), those 
transplanted after a delay of 200 days were rejected with a 
median survival time of 35 days. Significantly. when the 
primary graft remained in situ for >250 days, second donor-
specific grafts survived indefinitely. These data confirm that. 
in this model. continued unresponsiveness is dependent on 
the presence of the graft itself rather than on cells which may 
leave the graft and migrate to peripheral sites. It is interest-
ing to note in this context that there has been at least one 
clinical example in which evidence of donor-derived cells 
could be found in several recipient tissues after transplanta-
tion. but the cells were no longer detectable after graft rejec-
tion ( 71. Such observations suggest that in clinical transplan-
tation. which has been the focus of most of the interest in 
microchimerism, the continued presence of the graft might 
explain the evidence for donor-derived cells at tissue sites 
distant from the graft itself. 
Starzl et al. express the view that the way in which we 
assess grail functIOn in our cardiac allograft models mIght be 
regarded bv some as rather imprecise. In our laboratory. we 
define rejectIOn as either the loss of palpable cardiac contrac-
tIon or the loss of electncal activity as defined by ECG (8). 
Grafts are therefore classified as functioning only if they 
have hoth palpable contraction and ECG. We accept that. as 
with all anImal transplant models. the mouse heart model 
mav have limItations. and we fully support the view that 
det~lled histological analyses are requIred to determine 
whether long-term surviving hearts are completely free from 
tmmune-mediated damage. Such studies are currentlv 10 
progress 10 our laboratory. However. we believe that co~tin-
ued allograft function for greater than 100 days provides a 
robust demonstration of operational tolerance. The grounds 
for this conclusion are as follows: (1) the B 10 to C3H strain 
combination used in our experiments represents a mismatch 
for major plus multiple minor transplantation antigens; un-
treated animals reject their grafts in 8-12 days. (2) At 100 
days after transplantation, C3H recipients of B10 grafts 
transplanted in the anti-CD4IDST protocol frequently have 
ECG frequency ratios (graft/native) that approach or even 
exceed those obtained in syngeneic control animals at the 
same postoperative time point. (3) Animals with hearts sur-
viving beyond 100 days are truly tolerant, as judged by the 
stringent test of acceptance of second donor-specific heart 
grafts (MST> 100 days); third-party hearts are rejected 
acutely (MST= 16 days) (9, 10). (4) Adoptive transfer of 
5X 107 unfractionated splenocytes from C3H recipients with 
long-term B10 heart allografts leads to a significant prolon-
gation ofB10 hearts transplanted into unmodified naive C3H 
recipients (MST=82 days). 
It seems likely that much of the controversy surrounding 
the possible role of chimerism/microchimerism in clinical 
transplantation relates to the fact that these terms have been 
used to describe a number of rather disparate situations, few 
of which satisfy the most widely accepted definition of chi-
merism. In the classical sense, chimerism refers to the pres-
ence of allogeneic pluripotent stem cells which are capable of 
self-renewal and give rise to populations of multilineage dif-
ferentiated cells. If the criterion for chimerism was simply 
the presence of allogeneic cells of any type, surely every 
patient with a surviving allograft could be described as chi-
meric. We believe that the terms chimerismlmicrochimerism 
should be reserved for situations in which classical chimer-
ism can be clearly demonstrated, and we suggest that anti-
gen persistence be used in all other cases. A valuable contri-
bution to this discussion has recently been provided by 
Kawai et a1. (J ll, who administered donor bone marrow to 
irradiated, anti-thymocyte globulin-treated cynomolgus mon-
keys then examined the recipients for multilineage chimer-
ism using flow cytometry. Perhaps the use of the term mul· 
tllineage chimerism by other authors mIght help to clarify 
this rather confused area of debate. 
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THE USE OF N-ACETYLCYSTEINE IN SOLID-ORGAN PRESERVATION SOLUTIONS 
We read with interest the article of Fukuzawa et a1. (1) 
concerning the reduction of reperfusion damages by N-ace-
tylcysteine (NAC) after warm hepatic ischemia. 
In this report, they conclude that NAC, intervening in 
glutathione (GSH) homeostasis, might limit the reperfusion 
injuries and improve graft survival. 
Recently, we have developed an original lung preservation 
solution (SPAL UP) in which the scavenger system is com-
posed of GSH and NAC (Table 1). This solution has been 
tested in vitro on different pulmonary parenchymal cells, 
such as alveolar type II cells (personal communication), fetal 
fibroblasts (2, 3), and, more recently, human pulmonary ar-
tery endothelial cells (data still not published). The effects on 
cellular viability were compared with those of other solid 
organ preservation solutions. Our research showed that 
SPAL UP significantly influenced pulmonary cell viability. 
Using isolated parenchymal cells as a lung preservation 
screening model. we are, at present, not able to explain these 
findings; nevertheless, regarding NAC as a component of our 
solution, we postulated different mechanisms of action. The 
-SH radicals of NAC might regenerate glutathione -SH 
groups oxidized by oxygen-derived free radicals during both 
ischemia and reperfusion phases and it might also take part 
directly in the reduction offree radicals. Moreover. NAC is an 
TABLE 1. SPAL UP compOSition 
Na' 
K-
CI-
~lgD • 
HCO" 
Ca 
Fe 
Glucose 
Albumin 
~lethylprednlsone 
.V -Acetvlcysteme 
GlutathIOne 
Osmolanty 
125 mEqlL 
4.2 mEqlL 
105 mEqlL 
:2 mEqlL 
25 mEqlL 
8.9 mgJdl 
133 ",gldl 
4.4 giL 
4.3 gldl 
20 mgJL 
300 mgtL 
300 mgtL 
275 mOsmtL pH 7.2 
important intracellular precursor of biochemical synthesis of 
GSH and readily traverses cellular membrane. When the 
temperature of preservation is about lOoC (as in our in vitro 
studies), cellular metabolism could still be active in part; 
thus, NAC might take part in intracellular regeneration of 
GSH. Nowadays, considering the indispensable presence of 
GSH in preservation solutions, we believe that, according 
to Fukuzawa et al. (1), the adjunctive use of an adequate 
NAC concentration (300 mglL in our solution) might improve 
both intracellular and extracellular GSH homeostasis, and 
thus possibly strengthen the oxygen free radical scavenger 
system. 
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